News

Medical device maker said it is working to assess the scope of the attack and business interruption.

Stocks wavered at the opening bell on Wednesday as investors assessed fresh inflation data and upcoming earnings from AI bellwether Nvidia.

Boston Scientific stock falls as the medical device maker announces the latest batch of bad news for the company.

Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.

Boston Scientific stock crumbled Wednesday after the company said a cybersecurity incident interrupted processing and shipping.

The medical device maker identified the incident on Tuesday and says the timeline for a full restoration is not yet known

(Updates with economic data, recent oil price changes, world markets' overview, and corporate stock

The attack affected global operations, and its full scope is still being determined, the medical device maker said in a securities filing.

Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.

Boston Scientific (NYSE:BSX) disclosed on Tuesday that a cybersecurity incident has affected some of its information technology systems, disrupting parts of the medical device company’s operations. Shares of Boston Scientific fell 4% in premarket trading on Wednesday following the disclosure.

The medical device-maker says it cannot yet determine any financial impact from the attack it suffered this week.

Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.

Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.

Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.

Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.

TFX's $1.5B OEM sale cuts leverage and lifts 2026 EPS guidance, but weaker growth and margin pressure keep the outlook measured.

Its capital budget has overtaken its research budget for the first time in the fifteen years on record, and two of the seven launches management is counting on to restore growth come from outside its own labs.

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]

Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2.0b. The completed buyback represents 2.69% of the company’s shares. This update provides an additional data point on how Boston Scientific is allocating capital and managing its share count. It also offers a clearer backdrop for assessing recent stock performance and earnings expectations. See...

In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic sales growth guidance. Although the CHAMPION-AF trial met all clinical endpoints, it did not act as a meaningful catalyst for the business outlook, and the contrast between bullish...

Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trading below what the fundamentals imply. That gap between weak recent returns and an undervalued read is now front of mind for anyone looking at the current US$51.83 share price. Over the last 12 months, Boston Scientific has declined 49.8%, which puts recent investor sentiment and the current...

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500’s 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as […]

Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, […]

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.

Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year.